Modern Induction Therapy for Transplantineligible Multiple Myeloma Patients: Literature of Review

International Journal of Medical Science

© 2015 by SSRG - IJMS Journal

Volume 2 Issue 6

Year of Publication : 2015

Authors : Dr. Kalita Lohit kumar , Dr. Gogoi Pabitra Kamar and Dr. Sarma Umesh Ch

10.14445/23939117/IJMS-V2I6P102

How to Cite?

Dr. Kalita Lohit kumar , Dr. Gogoi Pabitra Kamar and Dr. Sarma Umesh Ch, "Modern Induction Therapy for Transplantineligible Multiple Myeloma Patients: Literature of Review," SSRG International Journal of Medical Science, vol. 2,  no. 6, pp. 7-11, 2015. Crossref, https://doi.org/10.14445/23939117/IJMS-V2I6P102

Abstract:

Multiple myeloma (MM) is a clonal plasma cell malignancy, characterized by the proliferation of neoplastic plasma cells the first case was documented in the literature in the year 1844. The current therapeutic strategy for multiple myeloma has witnessed a dramatic improvement when compared with the rhubarb pill and infusion of orange peel that were used in 1844. It is still an incurable disease but the introduction of novel therapies has altered the natural course of the disease, transforming it into a chronic disease from a terminal illness

Keywords:

myeloma, survival, remission

References:

[1] Kyle A, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351 (18):1860-73.
[2] Kumar SK, Mikhael JR, Buadi FK, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin Proc. 2009;84(12):1095-10.
[3] Schwartz RN, Vozniak M. Current and Emerging Treatments f0r Multiple Myeloma. J Manag Care Pharm. 2008;14(7)(suppl S):512-S18.
[4] Jagannath S. Treatment of myeloma in patients not eligible for transplantation. Curr Treat Options Oncol. 2005;6(3):241-53.
[5] Facon T, Darre S. Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Clinical Hematology. 2007;20(4):737-46.
[6] Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet. 2007; 370(9594):1209-18.
[7] Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma; IFM 01/01 Trial. J Clin Oncol. 2009;27:3664-70.
[8] Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood. 2008;112:3107-14.
[9] Waage A, Gimsing P, Juliusson G, et al. myeloma: a placebo controlled randomized phase 3 trial. Blood. 2007,110: Abstract 78a.
[10] Wijermans PW, Zweegman S, van Marwijk Kooy M, et al. MP versus MPT in elderly myeloma patients: The final outcome of the HOVON-49 study [abstract 116]. Clin Lymphoma Myeloma. 2009;9(1 suppl):S14.
[11] Ludwig H, Hajek R, Tothova E, et al. Thalidomide—dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2008,11:3435-42.
[12] Owen RG, Morgan GJ, Jackson H, et al. MRC Myeloma IX: Preliminary results from the non-intensive study [abstract 547]. C/in Lymphoma Myeloma. 2009;9(1 supp|):79.
[13] Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133—42.
[14] Dimopoulos M, Spencer A, et al M, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl Med. 2007;357(21):2123-32.
[15] Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open—label randomised controlled trial. Lancet Oncol. 2010;11(l):29-37.
[16] Palumbo A, Falco P, Corradini P, et al. Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GlMEMA-Italian Multiple Myeloma Network.  Clin Oncol. 2007;25(28):4459-65.
[17] Palumbo A, Dimopoulos MA, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma Blood. 2009;114:Abstract 613.
[18] Ludwiga H, Beksacb M, Bladéc J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 201 O;15(1):6-25.
[19] Mateos MV, Herna’ndez 1M, Herna'ndez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165-72.
[20] San Miguel J , Schlag R, Khuageva NK, et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med. 2008;359(9):906-17.
[21] Mateos MV, Herna’ndez JM, Herna'ndez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time—t0—events results and prognostic factors for time to progression. Haematologica. 2008;93(4):560-5.
[22] San Miguel l, Schlag R, Khuageva N, et al. Updated follow-up and results of subsequent therapy in the phase Ill VISTA trial: Bortezomib plus melphalan-prednisone versus melphalan—prednisone in newly diagnosed multiple myeloma [abstract 650]. Blood. 2008;112:242.
[23] NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma 2010. Available from www.nccn.org.
[24] Mateos MV, Oriol A, Martinez j, et al. A Prospective, Multicenter, Randomized, Trial of bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/ Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years. Blood. (ASH Annual Meeting Abstracts). 2009,1 l4:Abstract 3.
[25] Niesvizky R, Reeves j, Flinn IW, et al. Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients. Blood. (ASH Annual Meeting Abstracts). 2009;1 14:Abstract 129.
[26] Palumbo A, Bringhen S, Rossi D, et al. Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance  with Bortezomib and Thalidomide for initial Treatment of Elderly Multiple Myeloma patients. Blood. (ASH Annual Meeting Abstracts). 2009;114: Abstract 128.